+44 (0)20 3910 4640 hello@symmetron.net

CAncer

 

The cancer drugs fund in practice and under the new framework

PharmacoEconomics. 2019:1-10.

Authors

Sabry-Grant C, Malottki K, Diamantopoulos A

Noteworthy

This is the first study investigating the Cancer Drugs Fund under the new framework. We developed a method to systematically identify documents and collect information regarding the drugs included in the Fund.

Process

\

Designed a protocol to identify, collect and synthesise data on the drugs included in the Cancer Drugs Fund under the new framework

\

NICE and SMC documents were reviewed to capture information pertaining to drugs involved in a managed access agreement on the Cancer Drugs Fund

\

Information was collected and synthesised on clinical and economic aspects of the treatments included in the Cancer drugs Fund

\

Considered recent criticism of the CDF and how the new framework in practice may address or confirm those limitations

Publications in other disease areas

Atrial fibrillation

Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke

Cancer

Societal costs of Er+/Her2- advanced or metastatic breast cancer in post-menopausal women in the United Kingdom

Idiopathic pulmonary fibrosis

The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review

Psoriasis

The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis

Rheumatoid arthritis

Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK

 

Venous thromboembolism

Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective